CareDx reported a strong first quarter 2025, with total revenue increasing 18% year-over-year to $84.7 million. The company achieved its seventh consecutive quarter of sequential testing services volume growth and significantly improved its adjusted EBITDA to $4.6 million from a loss in the prior year.
Total revenue for Q1 2025 was $84.7 million, an 18% increase year-over-year.
Testing services revenue grew 15% year-over-year to $61.9 million, with volume increasing 12% to approximately 47,100.
The company reported a GAAP net loss of $10.4 million but a non-GAAP net income of $5.4 million and positive adjusted EBITDA of $4.6 million.
CareDx reaffirmed its full-year 2025 revenue guidance of $365 million to $375 million and adjusted EBITDA guidance of $29 million to $33 million.
CareDx reaffirmed its full-year 2025 guidance, expecting revenue between $365 million and $375 million and adjusted EBITDA between $29 million and $33 million. The company also set a 2027 target of $500 million in revenue and $100 million in adjusted EBITDA.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance